Cargando…

Elevated glypican‐1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is the most lethal cancer in humans, with a 5‐year survival rate of <5%. Recently, glypican‐1 (GPC1)‐expressing circulating exosomes were found to be a promising diagnostic tool for PDAC. However, the aberrant expression of GPC1 has not been systematically...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Haizhen, Niu, Fangfei, Liu, Fang, Gao, Jiajia, Sun, Yulin, Zhao, Xiaohang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5463070/ https://www.ncbi.nlm.nih.gov/pubmed/28440066 http://dx.doi.org/10.1002/cam4.1064

Ejemplares similares

High levels of serum glypican‐1 indicate poor prognosis in pancreatic ductal adenocarcinoma
por: Zhou, Cong‐ya, et al.
Publicado: (2018)

Neutrophil–lymphocyte ratio (NLR) was associated with prognosis and immunomodulatory in patients with pancreatic ductal adenocarcinoma (PDAC)
por: Xiang, Zi-jun, et al.
Publicado: (2020)

KRT8 and KRT19, associated with EMT, are hypomethylated and overexpressed in lung adenocarcinoma and link to unfavorable prognosis
por: Wang, Wenlong, et al.
Publicado: (2020)

Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels
por: Du, Jiali, et al.
Publicado: (2020)

Serum exosomal and serum glypican-1 are associated with early recurrence of pancreatic ductal adenocarcinoma
por: Zhao, Juan, et al.
Publicado: (2022)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
por: Rogers, Jane E., et al.
Publicado: (2020)

A feasible CT feature to differentiate focal‐type autoimmune pancreatitis from pancreatic ductal adenocarcinoma
por: He, Chaobin, et al.
Publicado: (2019)

Usefulness of (18)F‐fluorodeoxyglucose positron emission tomography/computed tomography for predicting the prognosis and treatment response of neoadjuvant therapy for pancreatic ductal adenocarcinoma
por: Yokose, Takahiro, et al.
Publicado: (2020)

Reducing nihilism in metastatic pancreatic ductal adenocarcinoma: Treatment, sequencing, and effects on survival outcomes
por: O'Reilly, Eileen M., et al.
Publicado: (2020)

Research progress and design optimization of CAR‐T therapy for pancreatic ductal adenocarcinoma
por: Li, Tianjiao, et al.
Publicado: (2019)

Prognostic value of γ‐glutamyltransferase‐to‐albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery
por: Li, Shuo, et al.
Publicado: (2019)

A novel rapid quantitative method reveals stathmin‐1 as a promising marker for esophageal squamous cell carcinoma
por: Yan, Lu, et al.
Publicado: (2018)

Differentiation of atypical pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinomas: Using whole‐tumor CT texture analysis as quantitative biomarkers
por: Li, Jiali, et al.
Publicado: (2018)

Dissecting cell-type-specific metabolism in pancreatic ductal adenocarcinoma
por: Lau, Allison N, et al.
Publicado: (2020)

Associations between ABO blood groups and pancreatic ductal adenocarcinoma: influence on resection status and survival
por: El Jellas, Khadija, et al.
Publicado: (2017)

Real‐world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma
por: Yu, Kenneth H., et al.
Publicado: (2021)

The Proteoglycan Glypican-1 as a Possible Candidate for Innovative Targeted Therapeutic Strategies for Pancreatic Ductal Adenocarcinoma
por: Busato, Davide, et al.
Publicado: (2022)

Prognostic value of Glypican family genes in early-stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy and possible mechanisms
por: Liu, Jun-Qi, et al.
Publicado: (2020)

Disparities in Pancreatic Ductal Adenocarcinoma—The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes
por: Riner, Andrea N., et al.
Publicado: (2020)

Development and validation of novel nomograms for predicting the survival of patients after surgical resection of pancreatic ductal adenocarcinoma
por: Li, Ge, et al.
Publicado: (2020)

Spatial determination and prognostic impact of the fibroblast transcriptome in pancreatic ductal adenocarcinoma
por: Croft, Wayne, et al.
Publicado: (2023)

The limits of molecular signatures for pancreatic ductal adenocarcinoma subtyping
por: Lautizi, Manuela, et al.
Publicado: (2022)

Multilevel regulation of RUVBL2 expression predicts poor prognosis in hepatocellular carcinoma
por: Yan, Tao, et al.
Publicado: (2019)

Analysis of distinct long noncoding RNA transcriptional fingerprints in pancreatic ductal adenocarcinoma
por: Yu, Xiang, et al.
Publicado: (2017)

Tumor copy number instability is a significant predictor for late recurrence after radical surgery of pancreatic ductal adenocarcinoma
por: Wen, Chenlei, et al.
Publicado: (2020)

The PD-L1 Expression and Tumor-Infiltrating Immune Cells Predict an Unfavorable Prognosis in Pancreatic Ductal Adenocarcinoma and Adenosquamous Carcinoma
por: Zhang, Zhiwei, et al.
Publicado: (2023)

Intratumoral neutrophil extracellular traps are associated with unfavorable clinical outcomes and immunogenic context in pancreatic ductal adenocarcinoma
por: Chen, Xianlong, et al.
Publicado: (2022)

The clinical relevance of the Hippo pathway in pancreatic ductal adenocarcinoma
por: Drexler, Richard, et al.
Publicado: (2020)

Expression of SNAIL in accompanying PanIN is a key prognostic indicator in pancreatic ductal adenocarcinomas
por: Fujiwara, Sho, et al.
Publicado: (2019)

Cancer‐associated fibroblasts promote M2 polarization of macrophages in pancreatic ductal adenocarcinoma
por: Zhang, Aibin, et al.
Publicado: (2017)

High GFPT1 expression predicts unfavorable outcomes in patients with resectable pancreatic ductal adenocarcinoma
por: Gong, Yitao, et al.
Publicado: (2021)

An immature inhibin‐α‐expressing subpopulation of ovarian clear cell carcinoma cells is related to an unfavorable prognosis
por: Kusumoto, Shinya, et al.
Publicado: (2021)

Irreversible electroporation augments β-glucan induced trained innate immunity for the treatment of pancreatic ductal adenocarcinoma
por: Woeste, Matthew R, et al.
Publicado: (2023)

Pancreatic Ductal Adenocarcinoma: Relating Biomechanics and Prognosis
por: MacCurtain, Benjamin M., et al.
Publicado: (2021)

Prognostic value of Kinesin‐4 family genes mRNA expression in early‐stage pancreatic ductal adenocarcinoma patients after pancreaticoduodenectomy
por: Han, Quanfa, et al.
Publicado: (2019)

Distal bile duct carcinomas and pancreatic ductal adenocarcinomas: postulating a common tumor entity
por: Schmuck, Rosa B., et al.
Publicado: (2015)

Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening
por: Cremin, Carol, et al.
Publicado: (2020)

Impact of the COVID-19 Pandemic on Management of Patients with Metastatic Pancreatic Ductal Adenocarcinoma in the United States
por: Paluri, Ravi, et al.
Publicado: (2022)

Noteworthy prognostic value of phospholipase C delta genes in early stage pancreatic ductal adenocarcinoma patients after pancreaticoduodenectomy and potential molecular mechanisms
por: Zhou, Xin, et al.
Publicado: (2019)

Modulation of myeloid and T cells in vivo by Bruton’s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
por: Sinha, Meenal, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dekti4992itabj3nqueolcj3cu